Please login to the form below

Not currently logged in
Email:
Password:

Jacques Dumas joins Nosopharm scientific advisory board

French biotech's appointments also include Dominique Breilh

Nosopharm has appointed Jacques Dumas and three others to its scientific advisory board to strengthen its preclinical development programme.

Dumas, who has over 20 years of experience of antibiotic R&D, has previously held positions as chief scientific officer at Idenix Pharmaceuticals and VP and head of strategy for AstraZeneca infectious diseases unit.

He is joined on Nosopharm's scientific advisory board by Dominique Breilh, Jean-Michel Molina and Patrice Nordmann.

Dominique Breilh runs the pharmacokinetics and clinical pharmacy laboratory at the University of Bordeaux, France; Jean-Michel Molina is professor of infectious diseases at the University of Paris Diderot; and Patrice Nordmann is professor and director of the molecular microbiology unit at Switzerland's University of Fribourg.

French biotech company Nosopharm, which focus on anti-infective research, said the four appointments reflect a new phase of development for Odilorhabdins, a novel class of antibiotics it is developing.

Philippe Villain-Guillot, CEO of Nosopharm, said: “Dominique Breilh, Jacques Dumas, Jean-Michel Molina and Patrice Nordmann have internationally renowned skills and knowledge, which is a major asset for Nosopharm.

“Their appointments reflect our desire to ramp up our development. Our aim is to run phase I clinical trials starting in 2017 to evaluate a first-generation Odilorhabdin derived from out NOSO-95 molecule.”

19th November 2014

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Apex.co.uk Conferences, Events and Exhibition Stands

Apex.co.uk is one of the UK’s leading event and exhibition agencies, specialising in healthcare. We understand your communication goals, whether...

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics